Results 151 to 160 of about 11,928,997 (202)
Some of the next articles are maybe not open access.
Effect of lovastatin on hemorheology in type II hyperlipoproteinemia
Atherosclerosis, 1990To assess the effect of lovastatin on blood rheology, the hemorheological determinants fibrinogen, red cell aggregation, plasma viscosity, hematocrit and platelet aggregation (spontaneous and ADP-induced) were studied in 15 patients with type II hyperlipoproteinemia in the course of treatment with lovastatin.
R, Koppensteiner, E, Minar, H, Ehringer
openaire +2 more sources
Neonatal Diagnosis of Familial Type II Hyperlipoproteinemia
Pediatrics, 1976Cord serum prebeta-β-lipoprotein concentrations, was measured in a radial immunodiffusion assay in 303 randomly selected, full-term infants whose parental phenotypes were unknown. Six infants had elevated concentrations, that is above a cut-off limit of 197 mg/100 ml (97.5th percentile).
G E, Andersen, B, Friis-Hansen
openaire +2 more sources
Therapeutic failure in familial type II hyperlipoproteinemia
Metabolism, 1976The extended use of diet and cholestyramine therapy in familial type II hyperlipoproteinemia was examined in patients who previously participated in a short-term, double-blind trial. A striking secondary failure in therapeutic response during 4 yr of use of this therapy was noted with plasma cholesterol rising an average of 15%.
L A, Witters +4 more
openaire +2 more sources
Kyrle's Disease and Type II Hyperlipoproteinemia
Archives of Dermatology, 1980Kyrle's disease is an uncommon dermatosis of hyperkeratotic papules, with a distinctive histologic picture characterized by the penetration of a keratotic plug into the dermis. We report a case of Kyrle's disease in association with type II hyperlipoproteinemia.
K J, Tomecki +2 more
openaire +3 more sources
Sitosterol in Type II Hyperlipoproteinemia
1976In 1951, PETERSON reported that the increase of plasma cholesterol levels in chickens caused by cholesterol feeding can be prevented by including 1 % soybean sterols in the diet (18). Since then, numerous investigators have demonstrated a hypocholesterolemic action of plant sterols, especially beta-sitosterol, in experimental animals and man (2, 3, 7 ...
P. Oster +9 more
openaire +1 more source
Results of colestipol therapy in type II hyperlipoproteinemia
Atherosclerosis, 1976Twenty-five patinets with well defined Type ii hyperlipoproteinemia were treated with a divided 15 g daily dose of colestipol, a bile acid sequestrant, for periods of up to 20 months. The patients were divided into 3 groups: Those with no obvious sequelae, those with arcus corneae, xanthomas, and/or xanthelasmas only, and those with atherosclerotic ...
A M, Lees, M A, McCluskey, R S, Lees
openaire +2 more sources
Controlled trial of acifran in type II hyperlipoproteinemia
Clinical Pharmacology and Therapeutics, 1985The hypolipidemic effects of acifran were evaluated in a randomized, double-blind, placebo-controlled study of 30 patients with type IIa hyperlipoproteinemia. Plasma lipid and lipoprotein values were determined at baseline (mean of three values), again after a 2-week single-blind period of acifran dosing, and at 2-week intervals during a 10-week period
D B, Hunninghake +3 more
openaire +2 more sources
Pseudohomozygous and Pseudoheterozygous Type II Hyperlipoproteinemia
Archives of Pediatrics & Adolescent Medicine, 1976A 4-year-old boy had typical features of homozygous type II hyperlipoproteinemia with planar xanthomas, a plasma cholesterol level greater than 600 mg/dl, and an estimated beta-lipoprotein cholesterol concentration greater than 500 mg/dl. Both he and his sister, who had the biochemical features of the heterozygous state, responded unusually well to a ...
openaire +2 more sources
Neomycin and plasma lipoproteins in type II hyperlipoproteinemia
Clinical Pharmacology and Therapeutics, 1984Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9-mo, double-blind, randomized, crossover, placebo-controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safety, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%
Jeffrey M Hoeg +14 more
openaire +2 more sources
Secondary type II hyperlipoproteinemia in patients with anorexia nervosa
Metabolism, 1978In 18 patients with anorexia nervosa, plasma cholesterol and triglyceride concentral concentrations were repeatedly determined over a period of 14 mo. In 11 patients elevated cholesterol concentrations were found which were due to an increase of low-density lipoprotein cholesterol, whereas high-density lipoprotein and very low density lipoprotein ...
R, Mordasini, G, Klose, H, Greten
openaire +2 more sources